14 completed. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 1 | 3 | Completed 3 |
Follow Refractory Hairy Cell Leukemia: new trials by email Literature Review of Refractory Hairy Cell Leukemia trials Research Report on Refractory Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Fludarabine, Busulfan, Total Body Irradiation (TBI) - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2011-08-04 | 2026-04-15 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 63 | 2009-02-01 | 2018-01-02 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant ondansetron, survey administration, management of therapy complications - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 49 | 2008-08-08 | 2017-05-23 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer alemtuzumab, total-body irradiation, fludarabine phosphate - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 12 | 2005-03-01 | 2017-05-30 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer fludarabine phosphate, total-body irradiation, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 150 | 2004-04-01 | 2020-01-29 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 37 | 2003-09-01 | 2020-01-18 |
| Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies alemtuzumab, fludarabine phosphate, total-body irradiation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2001-11-01 | 2020-01-29 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
Hodgkin Disease (14) · Leukemia, Hairy Cell (14) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma, Follicular (14) · Lymphoma, Non-Hodgkin (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Large-Cell, Immunoblastic (13) · Lymphoma, Mantle-Cell (13) · Burkitt Lymphoma (12) · Lymphoma, T-Cell, Cutaneous (12) · Mycosis Fungoides (12) · Sezary Syndrome (12) · Waldenstrom Macroglobulinemia (12)
Blood Protein Disorders (14) · Cardiovascular Diseases (14) · Chronic Disease (14) · Disease Attributes (14) · Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Hemorrhagic Disorders (14) · Hemostatic Disorders (14) · Immune System Diseases (14) · Immunoproliferative Disorders (14) · Leukemia (14) · Leukemia, B-Cell (14) · Leukemia, Lymphoid (14) · Lymphatic Diseases (14) · Lymphoma (14)
Peripheral Blood Stem Cell Transplantation (8) · Mycophenolic Acid (7) · Whole-Body Irradiation (7) · fludarabine phosphate (7) · Cyclosporine (5) · Tacrolimus (5) · Methotrexate (3) · merphos (3) · Alemtuzumab (2) · Rituximab (2) · Beclomethasone (1) · Bendamustine Hydrochloride (1) · Busulfan (1) · Cyclophosphamide (1) · MK 2206 (1)
Fred Hutchinson Cancer Center (8) · National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Chicago (1)
United States (14) · Italy (5) · Germany (1)
Brenda Sandmaier (3) · David Maloney (3) · George Chen (1) · Hongtao Liu (1) · John Gerecitano (1) · Leona Holmberg (1) · Paul Martin (1) · Pavan Reddy (1) · Usama Gergis, MD (1) · Yasuhiro Oki (1)
PMID 32499241, PMID 19900571, PMID 26213141, PMID 28314788, PMID 31481800
P30CA015704 (6), P01CA018029 (3), P01CA078902 (3), N01CM00039 (1), N01CM62202 (1), P30CA008748 (1), P30CA016672 (1), P30CA046592 (1), U01CA069856 (1)